Enterprise Europe Network

A dermatological composition for treating inflammatory skin diseases is offered for licensing

Country of origin:
External Id: 
Last update
Expiration date


Partner keyword: 
Virus, Virology/Antibiotics/Bacteriology
Biochemistry / Biophysics
Cellular and Molecular Biology
Biochemistry / Biophysics
Cellular and Molecular Biology
Anatomy, Pathology, Immunology, Physiology
Other research and experimental development on natural sciences and engineering


Researchers from a Spanish university have developed a number of molecular compounds with anti-inflammatory properties. This innovative composition contains an active ingredient isolated from pig lard that modulates the inflammatory processes efficiently and reduces side effects associated to synthetic products. European cosmetic companies with broad experience in the segment of skin care and capable of conducting in vivo studies for developing a cosmetic product, are being sought for licensing.



Inflammatory events are the principle cause of rapid extrinsic and intrinsic skin aging. Inflammatory events in the skin lead to a reduction in collagen gene activity, alter proliferation rates of cells in all skin layers, cause a thinning of the epidermis, a flattening of the dermo-epidermal junction, and an increase in irregular pigment production. It is important, in the cosmetic sector, to find natural compounds that inhibit the production of inflammatory molecules in the skin and develop topical products to avoid inflammation and retard or even reverse the skin aging process.

A Spanish research group specialized in biochemistry has developed an innovative topical treatment from 5-dodecanolida involved in inflammatory response. It reduces considerably skin inflammation related to bacterial infections and shows no toxicity levels.

The formulations of the present invention may be commercially available or obtained by chemical synthesis or through an extraction and purification process from pig lard from which researchers have developed principle agents. These compounds with anti-inflammatory properties are generated physiologically allowing the effective modulation of inflammatory processes and the reduction of side effects. Low concentrations are needed to reduce anti-inflammatory action that reveals their anti-inflammation power. The administration route is variable and the composition can change depending on it. However, the topical administration is preferred as an ointment or cream.

Anti-inflammatory properties of active ingredients have been tested through in-vitro and in-vivo experiments with laboratory animals and human immune cells. A toxicity study on 5- dodecanolide has been also conducted. It has demonstrated that in comparison with other commercial anti-inflammatory products, the compound shows no toxicity.

European cosmetic companies capable to conduct in-vivo and clinical trials necessary to continue developing a cosmetic product are being sought for a license agreement.

Advantages & innovations

Cooperation plus value: 
The present invention concerns chemical compounds that are generated naturally in living organisms and regulate inflammatory processes. As anti-inflammatory activity has never been described before in active ingredients of pig lard this innovative treatment opens a new field of study. The composition for topical treatment from the active ingredient in addition to other compounds could vary depending upon administration route: ointment, cream, gel, paste or spray. The required concentrations of the active ingredient for its anti-inflammatory action are low, showing a high anti-inflammatory power.

Stage of development

Cooperation stage dev stage: 
Field tested/evaluated

Partner sought

Cooperation area: 
European cosmetic companies specialized in the skin care sector are being sought for a license agreement. The company should be able to conduct in-vivo and clinical trials that are necessary to continue developing a cosmetic product for the treatment of inflammatory processes.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500


Dissemination sector group : 
Dissemination preferred : 
Belgium, Denmark, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom